Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00410761 · OUTCOME

Disease Control Rate (DCR)

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer · Source last updated 2025-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent

What was measured

Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \>= 12 weeks

Groups in this outcome

Vandetanib 300 mg

Vandetanib (300 mg daily)

Placebo

Placebo daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vandetanib 300 mg231
Placebo100

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Vandetanib 300 mg200Not reportedNot reportedNot reportedNot reported
Placebo71Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        200
      2. group Id
        OG001
        value
        71
denoms
  1. counts
    1. group Id
      OG000
      value
      231
    2. group Id
      OG001
      value
      100
    units
    Participants
description
Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \>= 12 weeks
groups
  1. description
    Vandetanib (300 mg daily)
    id
    OG000
    title
    Vandetanib 300 mg
  2. description
    Placebo daily
    id
    OG001
    title
    Placebo
param Type
NUMBER
reporting Status
POSTED
time Frame
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent
title
Disease Control Rate (DCR)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice